Sloy Dahl & Holst LLC Raises Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Sloy Dahl & Holst LLC increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 10.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,353 shares of the company’s stock after acquiring an additional 723 shares during the period. Sloy Dahl & Holst LLC’s holdings in CRISPR Therapeutics were worth $460,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CWM LLC grew its position in CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company’s stock worth $26,000 after acquiring an additional 260 shares in the last quarter. Tradewinds Capital Management LLC grew its position in CRISPR Therapeutics by 545.5% in the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock worth $32,000 after acquiring an additional 600 shares in the last quarter. Blue Trust Inc. purchased a new position in CRISPR Therapeutics in the fourth quarter worth about $32,000. Headlands Technologies LLC purchased a new position in CRISPR Therapeutics in the third quarter worth about $34,000. Finally, Bourgeon Capital Management LLC grew its position in CRISPR Therapeutics by 1,000.0% in the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, General Counsel James R. Kasinger sold 2,801 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $78.26, for a total value of $219,206.26. Following the completion of the sale, the general counsel now owns 60,070 shares in the company, valued at approximately $4,701,078.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,913 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares of the company’s stock, valued at approximately $4,570,747.57. The disclosure for this sale can be found here. In the last quarter, insiders sold 114,410 shares of company stock worth $7,984,677. 4.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Royal Bank of Canada raised their price objective on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a research note on Thursday, February 22nd. Chardan Capital raised their price objective on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Barclays raised their price objective on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 22nd. Mizuho raised their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Finally, Wolfe Research started coverage on shares of CRISPR Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $74.93.

CRISPR Therapeutics Stock Down 1.8 %

CRISPR Therapeutics stock traded down $1.03 during trading on Wednesday, reaching $56.93. The stock had a trading volume of 234,928 shares, compared to its average volume of 1,830,881. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10. The business has a 50 day moving average price of $73.89 and a 200 day moving average price of $63.30.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The firm had revenue of $201.20 million during the quarter, compared to analysts’ expectations of $148.72 million. The firm’s revenue was up 3253.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.41) EPS. As a group, research analysts forecast that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.